Symbiotec signs 10-year protein production deal with European innovator

Symbiotec Pharmalab has signed a 10-year manufacturing agreement with an unnamed European alternative protein company, reserving capacity at its Ujjain campus in India and establishing expansion options that could take the program into millions of liters of fermentation capacity.

• Symbiotec secured a 10-year take-or-pay manufacturing agreement.
• Initial production will use existing fermentation infrastructure in Ujjain.
• A dedicated plant and additional expansion options are planned.

Announced on November 6, the contract development and manufacturing agreement will use a campus equipped with four 100,000-liter fermenters, modular downstream processing equipment and integrated quality assurance and quality control capabilities.

The agreement reserves dedicated capacity for the European partner throughout its term. Symbiotec withheld financial details because of confidentiality obligations and did not identify the customer or the specific protein covered by the contract.

The company outlined a staged production program. Manufacturing will begin at the existing facility, followed by a new dedicated plant with several hundred thousand liters of fermentation capacity. Contracted expansion options reserved for the customer would allow the program to grow into millions of liters.

These figures describe fermentation capacity rather than annual protein output. The announcement did not give a construction timetable for the dedicated plant or specify when commercial deliveries would begin.

“Our planet needs cleaner, greener ways to produce essentials, and we are glad to see the industry moving in that direction,” said Anil Satwani, Managing Director of Symbiotec Pharmalab.

The announcement described precision fermentation, which uses engineered microorganisms to produce proteins traditionally obtained from animals. However, it did not disclose the production organism, intended food applications or markets in which the customer plans to sell the ingredient.

For Symbiotec, the agreement adds a long-term customer commitment to its expansion into alternative protein manufacturing. Its established operations include pharmaceutical ingredients, contract development and manufacturing services, and complex injectables.

Founded in 1995, the company operates four manufacturing facilities in Madhya Pradesh and serves more than 200 customers across over 40 countries. Its pharmaceutical business includes corticosteroid and steroidal-hormone active pharmaceutical ingredients.

Symbiotec is applying its experience in microbial fermentation, plant construction and quality management to customers developing food ingredients and other biotechnology products. At Ujjain, fermentation vessels are supported by downstream processing equipment used to recover and prepare ingredients after fermentation.

The company previously outlined its ambitions for alternative proteins, human nutrition and bio-based specialty chemicals in an interview with Protein Production Technology International published in May 2025.

Arjun Satwani described a manufacturing campus with commercial fermentation equipment, a pilot line and land reserved for additional capacity. The company’s approach included helping customers move from development batches into larger production vessels, with process development and downstream processing support accompanying that progression.

“Many partners who began with development batches are now forecasting commercial-scale needs in the near future,” Satwani told PPTI in that interview.

He also described customers developing several products, each requiring manufacturing slots, and the need to plan capacity around those requirements.

The November agreement provides a concrete example of that expansion strategy, combining access to existing equipment with provision for a customer-specific plant and subsequent additions.

The take-or-pay structure is another significant feature. Such arrangements generally require a customer to purchase an agreed quantity or make a payment under the contract’s terms, providing a commercial commitment alongside the reservation of manufacturing capacity.

Symbiotec did not publish the minimum purchase commitments, payment provisions or other conditions attached to this agreement. Its disclosure therefore does not establish the revenue the contract will generate or the proportion of Ujjain’s existing capacity allocated to the European customer.

The manufacturing plan also separates initial production from future investment. The four existing fermenters provide the starting infrastructure, while the dedicated plant and contracted expansion options represent later stages of the program.

The agreement follows Symbiotec’s earlier description of a business designed to support customers from process development through commercial manufacturing. In that model, the production partner supplies infrastructure and operating expertise while the ingredient developer brings its product and process.

For the European customer, the disclosed arrangement secures dedicated manufacturing capacity over a decade, with room to expand at the same campus. Symbiotec has not announced the size or commissioning date of the first dedicated plant.

‍If you liked this, check these out...

• Fermentation at full throttle: Symbiotec’s big bet on bio-based manufacturing

• ADM reveals US$55.5 million investment in Clinton precision fermentation expansion

• Acies Bio expands fermentation capacity with new 30m³ facility in Slovenia